Get the Stockscreener App
0.3138
2.90%
0.00885
Scisparc Ltd stock is traded at $0.3138, with a volume of 95,586.
It is up +2.90% in the last 24 hours and up +14.65% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$0.305
Open:
$0.3074
24h Volume:
95,586
Relative Volume:
0.03
Market Cap:
$3.40M
Revenue:
$1.75M
Net Income/Loss:
$-5.68M
P/E Ratio:
-0.0644
EPS:
-4.8726
Net Cash Flow:
-
1W Performance:
+2.05%
1M Performance:
+14.65%
6M Performance:
+46.46%
1Y Performance:
-70.11%
1-Day Range:
$0.30
$0.3173
1-Week Range:
$0.297
$0.3195
52-Week Range:
$0.197
$1.79
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
0.3138 | 3.36M | 1.75M | -5.68M | 0 | -4.8726 |
|
ONC
Beone Medicines Ltd Adr
|
246.34 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.12 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.12 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.29 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc announces publication of Japanese patent application - MSN
SciSparc Unveils Japanese Patent for Novel Pain Relief Combination - TipRanks
SciSparc secures Japanese patent for pain relief combo By Investing.com - Investing.com South Africa
SciSparc Ltd. Announces Publication of Japanese Patent Application - marketscreener.com
SciSparc secures Japanese patent for pain relief combo - Investing.com
SciSparc Ltd. Announces Publication of Novel Japanese Patent for Enhanced Pain Management Therapy Combining Paracetamol and PEA - Nasdaq
SciSparc Announces Publication of Japanese Patent Application - GlobeNewswire
SciSparc's New Pain Relief Patent Could Make Paracetamol Safer for Millions - Stock Titan
SciSparc sets annual shareholder meeting for June 25 By Investing.com - Investing.com Nigeria
SciSparc sets annual shareholder meeting for June 25 - Investing.com Australia
SciSparc Ltd. Announces Annual General Meeting for June 2025 - TipRanks
SciSparc and Clearmind Secure European Patent for Cocaine Addiction Therapy - TipRanks
SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc. - Nasdaq
SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - Stock Titan
Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC) - The Globe and Mail
SciSparc Ltd: Weathering Stock Market Storms with 3.17M Market Cap - investchronicle.com
A review of SPRC’s current quarter earnings predictions - uspostnews.com
What's Going On With jeffs' Brands Today? - Benzinga
Jeffs' Brands to Sell Smart Repair Pro Unit, SciSparc Nutraceuticals Stake to Plantify Foods; Shares Jump - marketscreener.com
SciSparc and Clearmind file patent for eating disorder treatment - Investing.com
SciSparc and Clearmind file patent for eating disorder treatment By Investing.com - Investing.com India
SciSparc announces collaboration with Clearmind Medicine - TipRanks
SciSparc and Clearmind File Patent for Eating Disorder Treatment - TipRanks
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders - The Manila Times
SciSparc-Clearmind Collaboration Leads to Filing of - GlobeNewswire
Novel Eating Disorder Treatment Patent Filed for 70M Patient Market | SPRC Stock News - Stock Titan
3 Reasons OMI is Risky and 1 Stock to Buy Instead - The Globe and Mail
Thinking Of Selling SciSparc Ltd (NASDAQ: SPRC) Stock? Check This Out First - Stocksregister
SciSparc (NASDAQ:SPRC) Shares Down 6% – Here’s Why - Defense World
SciSparc Extends Deadline for Miza III Ventures Deal - TipRanks
SciSparc Ltd. Extends Merger Agreement with AutoMax Motors - TipRanks
SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 1,435.0% in March - Defense World
SciSparc announces resale of 61.21M shares by selling shareholders; shares down - MSN
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - Louisiana First News
SciSparc and Clearmind Advance Cocaine Addiction Treatment with South Korean Patent Application - TipRanks
Is the SciSparc Ltd (NASDAQ:SPRC) stock an investment opportunity? - US Post News
SciSparc Shares Are Soaring Monday: What's Going On? - Benzinga
Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addiction - Marketscreener.com
SciSparc announces publication of patent via Clearmind collaboration - TipRanks
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
SciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine Addiction - Nasdaq
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
SciSparc Extends $2 Million Loan to Support Automax?s Growth Following Automax?s Entry into Direct Import of JAC Electric Vehicles - Marketscreener.com
SciSparc Ltd. Agrees to Sell MitoCareX to N2OFF - TipRanks
SciSparc signs definitive agreement to sell MitoCareX to N2OFF - TipRanks
SciSparc to sell MitoCareX to N2Off for $700,000 - MSN
SciSparc divests MitoCareX stake for $700,000 and stock swa By Investing.com - Investing.com South Africa
SciSparc divests MitoCareX stake for $700,000 and stock swa - Investing.com
SciSparc Ltd. Announces Sale of MitoCareX Shares to N2Off for $700,000 and Stock Exchange Agreement - Nasdaq
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):